Food and Drug Administration (FDA)
NEWS
With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.
The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
New data from an ongoing late-stage study reinforced the safety and efficacy of Cosentyx (secukinumab) as a beneficial treatment for patients with psoriatic arthritis and ankylosing spondylitis.
Roche and privately-held cell therapy company SQZ will jointly develop oncology products based on antigen presenting cells (APCs) that are created by the SQZ platform.
A new study published Friday in JAMA reports that many dietary supplements consumed by people in the United States contain unapproved pharmaceutical ingredients in the over-the-counter products that pose a health risk for unsuspecting consumers.
The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded Allele Biotechnology and Pharmaceuticals a Small Business Innovative Research grant to develop therapies for sepsis.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee voted to recommend AcelRx Pharmaceuticals’ Dsuvia to manage moderate-to-severe pain.
JOBS
IN THE PRESS